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Reported mortality rates from Clostridium difﬁ  cile dis-
ease in the United States increased from 5.7 per million 
population in 1999 to 23.7 per million in 2004. Increased 
rates may be due to emergence of a highly virulent strain 
of C. difﬁ  cile. Rates were higher for whites than for other 
racial/ethnic groups.
C
lostridium difﬁ  cile is an anaerobic, gram-positive ba-
cillus that can cause considerable disease, including 
diarrhea, colitis, and septicemia, resulting in death (1). C. 
difﬁ  cile–associated disease (CDAD) primarily affects per-
sons >65 years. Risk factors include residence in hospitals 
and long-term care facilities and the use of antimicrobial 
medications (1–3). Incidence of CDAD has been increas-
ing, and severe cases are becoming more common (4,5). 
These changes in the incidence and severity of CDAD may 
be associated with the emergence of a more virulent strain 
of C. difﬁ  cile bacteria (5,6). Death rates associated with C. 
difﬁ  cile were reported to be increasing from 1999 to 2002 
in the United States and from 2001 to 2005 in England and 
Wales (7,8). However, no trend analysis was conducted to 
evaluate the rate of increase. We incorporated mortality 
data for the United States through the year 2004 to con-
duct trend analyses of CDAD-related deaths and to exam-
ine demographic characteristics and coexisting conditions 
reported in deaths from C. difﬁ  cile infection. 
The Study
CDAD-related deaths were identiﬁ  ed by using mul-
tiple cause-of-death data from national mortality records 
for 1999–2004. CDAD-related deaths were deﬁ  ned as all 
deaths for which the underlying cause of death or any of 
the contributing causes of death included the International 
Classiﬁ   cation of Diseases, 10th revision (ICD-10) code 
A04.7 (enterocolitis due to C. difﬁ  cile). Information about 
the size and demographic breakdown of the US population 
for each year during 1999–2004 was obtained from censal 
and intercensal year estimates with bridged race data (9,10). 
Age-adjusted mortality rates were calculated by using the 
age distribution of the 2000 US population as a standard 
(11). The US population was divided into 5 racial/ethnic 
categories: white, Hispanic, Asian/Paciﬁ  c Islander, black, 
and American Indian/Alaska Native.
During 1999–2004, CDAD was reported as a cause of 
death for 20,642 persons. CDAD was reported as the un-
derlying cause for 12,264 (59%) of these deaths. A total 
of 3,256 deaths were reported related to all other intestinal 
infectious diseases combined (ICD-10 codes A00 to A09, 
excluding A047) over the same period. The median age of 
death for CDAD patients was 82 years. Age-adjusted mor-
tality rates from CDAD were slightly higher for men than 
for women (Table) and were higher for whites than for any 
other racial/ethnic group. Most CDAD-related deaths oc-
curred in hospitals (n = 16,557, 80%); 1,634 (8%) occurred 
in long-term care facilities, and 2,027 (10%) occurred at 
home.
Common coexisting conditions for CDAD-related 
deaths included septicemia (n = 7,654, 37%), renal failure 
(n = 4,786, 23%), pneumonia (n = 3,430, 17%), urinary 
tract infection (n = 1,496, 7%), and anemia (n = 785, 4%). 
HIV was reported for 81 CDAD-related deaths (<1%). 
However, among the 697 deaths reported in persons 25–54 
years of age, HIV was reported for 72 (10%).
The overall rate of C. difﬁ  cile–related deaths during 
the study period was 12.2 deaths per million population. 
Mortality rates related to CDAD increased during the study 
period (Figure), rising from 5.7 deaths per million popula-
tion in 1999 to 23.7 deaths per million population in 2004. 
Poisson regression estimates showed mortality rates in-
creased by 35% per year (coefﬁ  cient = 0.30, standard error 
= 0.004, 95% conﬁ  dence interval = 0.29–0.31) during the 
study period.
Conclusions 
Due to the inclusion of CDAD-related deaths when 
CDAD was not reported as the underlying cause of death, 
reported death rates in this study were higher than those 
published in an earlier analysis of CDAD-related deaths in 
the United States (7). C. difﬁ  cile is a cause of a substantial 
and increasing proportion of deaths in the United States 
and may be underrecognized as a cause of death. Little at-
tention has been paid to C. difﬁ  cile prevention; media and 
public health awareness efforts have focused largely on 
the prevention of disease from other intestinal pathogens 
such as Escherichia coli or Salmonella spp. However, the 
incidence of deaths from C. difﬁ  cile is greater than the ex-
tent of deaths from all other intestinal infectious diseases 
combined. C. difﬁ  cile–related mortality rates were higher 
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for whites than for other racial/ethnic groups. Racial/eth-
nic differences in insurance status and access to care (12) 
may render elderly whites more likely to receive treatment 
with antimicrobial drugs that put them at risk for C. dif-
ﬁ  cile infection. However, genetic or other factors may also 
be involved, and further research is needed to determine 
the causes of racial/ethnic differences in C. difﬁ  cile–related 
deaths.
Previous research showed increases in CDAD-related 
mortality rates in the United States until 2002 (7,8). This 
analysis estimates the rate of increase at 35% per year, and 
shows that mortality rates continued to increase at least 
until 2004. Increases in incidence and deaths from CDAD 
may be associated with the emergence of a new and more 
virulent strain of C. difﬁ  cile (5). The emergence of virulent 
strains of C. difﬁ  cile makes continued assessment of mor-
tality statistics important.
Infection with C. difﬁ  cile is associated with recent use 
of antimicrobial medications and with residence in hos-
pitals. Most CDAD cases are acquired in healthcare set-
tings (1), and as many as 90% of cases may be associated 
with antimicrobial drug use (2,3). High C. difﬁ  cile death 
rates call attention to the importance of proper infection 
control practices in hospitals and long-term care facilities 
and the judicious use of antimicrobial medications. Further 
research is needed to explore current questions concern-
ing which antimicrobial medications, if any, will lead to 
CDAD (13,14).
Infections such as septicemia, pneumonia, and urinary 
tract infections were commonly reported in conjunction 
with C. difﬁ  cile–related deaths. For some of these patients, 
the administration of antimicrobial medications to treat in-
fections from other pathogens may have paved the way for 
infection with C. difﬁ  cile. However, other risk factors are 
known, so that in many cases the careful use of antimicro-
bial agents may not be enough to prevent C. difﬁ  cile infec-
tion. HIV infection was only reported in a small fraction of 
CDAD–related deaths. However, immunosuppression and 
the use of prophylactic antimicrobial drugs in persons with 
AIDS may increase the risk for CDAD (15), and the effects 
of HIV should not be overlooked. In persons 25–54 years 
Table. Demographic characteristics of patients with Clostridium difficile–related deaths, United States, 1999–2004
Demographic group  C. difficile–related deaths, no. (%) Age-adjusted mortality rate/million population
Sex 
 Female 12,468  (60) 11.8
 Male 8,174  (40) 12.7
Race/ethnicity 
 White 18,534  (90) 12.9
   Hispanic 602  (3) 7.2
   Black 1.304  (6) 9.3
   Asian/Pacific Islander 139 (1) 3.5
   American Indian/Alaska Native 63 (<1) 7.9
Age group, y
 <1 17  (<1) 0.7*
 1–4 11  (<1) 0.1*
 5–14 12  (<1) 0.1*
 15–24 24  (<1) 0.1*
 25–34 62  (<1) 0.3*
 35–44 171  (1) 0.6*
 45–54 464  (2) 2.0*
 55–64 1,159  (6) 7.6*
 65–74 3,238  (16) 29.3*
 75–84 7,859  (38) 104.0*
>85 7,623 (37) 287.1*
Total 20,642 12.2
*This statistic is not age-adjusted because it only pertains to 1 age group. 
Figure. Yearly Clostridium difﬁ  cile–related mortality rates per million 
population, United States, 1999–2004.Clostridium difﬁ  cile–related Mortality Rates
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of age, in whom HIV infection is most common, HIV in-
fection was reported in approximately one tenth of CDAD-
related deaths. Thus, HIV can considerably increase C. 
difﬁ  cile death rates for demographic groups in which HIV 
prevalence is high.
Death certiﬁ  cate data may underrepresent the extent of 
CDAD-related deaths. This analysis was limited to deaths 
in which ICD-10 code A047 (enterocolitis due to C. difﬁ  -
cile) was mentioned and may have failed to capture CDAD-
related deaths in which colitis was not present. In addition, 
death certiﬁ  cate data may be affected by reporting error. 
Supplemental information such as decedents’ medical his-
tories was unavailable. No data were available regarding 
which strains of C. difﬁ  cile were responsible for reported 
CDAD–related deaths.
C. difﬁ  cile is an underrecognized cause of severe ill-
ness and death. This analysis underscores the importance 
of CDAD as a public health problem and the increasing 
incidence of CDAD-related deaths in the United States.
Mr Redelings is an epidemiology analyst with the Los An-
geles County Department of Public Health. He previously served 
as a humanitarian worker in Sudan. His current research interests 
include the epidemiology of gastrointestinal infections and the 
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